cardioselectivity

car·di·o·se·lec·tiv·i·ty

(kar'dē-ō-sĕ-lek-tiv'i-tē),
The relatively predominant cardiovascular pharmacologic effect of a drug with multipharmacologic effects; used especially when describing beta-blocking agents.

car·di·o·se·lec·tiv·i·ty

(kahr'dē-ō-sĕ-lek-tiv'i-tē)
The relatively predominant cardiovascular pharmacologic effect of a drug with multipharmacologic effects; used especially when describing beta-blocking agents.

cardioselectivity

(kard?e-o-se?lek?tiv'it-e) [ cardio- + L. seligere, to separate, select]
A stronger action on receptors in the heart than on those in the lungs. It is said of beta-adrenergic blocking agents that selectively block beta-1 receptors and thus do not cause bronchospasm.

Patient care

Patients with asthma or chronic obstructive pulmonary disease (COPD) should avoid high doses of nonselective beta-adrenergic drugs (beta blockers) because they can cause wheezing and shortness of breath. Patients with mild or moderate obstructive lung disease can safely use cardioselective beta blockers.

See: beta-adrenergic blocking agentcardioselective (kard?e-o-se?lek'tiv), adjective
Mentioned in ?
References in periodicals archive ?
Cruickshank, "The clinical importance of cardioselectivity and lipophilicity in beta blockers," American Heart Journal, vol.
In conclusion, cardioselectivity is paramount, and therefore metoprolol, bisoprolol and in particular nebivolol should be the first choice treatment.
Cardioselectivity is most pronounced at low doses and is lost at high doses.
The first factor is cardioselectivity. These agents, which include bisoprolol, metoprolol, atenolol, and acebutolol, are thought to selectively target the beta-receptors in the cardiovascular system and, thus, are safer to use in patients with asthma or chronic obstructive pulmonary disease due to the fact that exacerbations occur when the beta-1 receptors found in the lungs are blocked.